전립선암 치료 시장 규모, 점유율, 성장 분석 : 약제 종류별, 유통 경로별, 지역별 - 업계 예측(2026-2033년)

Prostate Cancer Treatment Market size was valued at USD 13.06 Billion in 2024 and is poised to grow from USD 14.09 Billion in 2025 to USD 25.88 Billion by 2033, growing at a CAGR of 7.9% during the forecast period (2026-2033).

The global prostate cancer treatment market reflects a vibrant and evolving landscape driven by rising incidences of prostate cancer among men. This growth is fueled by an increasing aging population, heightened awareness, and advancements in early diagnosis, leading to the development of innovative treatments and therapies. Nevertheless, challenges such as high treatment costs and the potential side effects associated with therapies may hinder broader adoption. Key market drivers include research and development investments, the introduction of complex pipeline drugs, and the rising demand for hormonal therapies in various cancer stages. Additionally, emerging economies offer significant growth opportunities, although challenges like prolonged healing periods in underdeveloped regions can impact market expansion. Personalized treatment approaches and improved drug targeting present further opportunities for enhancing patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Prostate Cancer Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Prostate Cancer Treatment Market Segments Analysis

Global Prostate Cancer Treatment Market is segmented by Drug Type, Distribution Channel and region. Based on Drug Type, the market is segmented into Hormonal Prostate Cancer Therapy, Prostate Cancer Chemotherapy, Prostate Cancer Immunotherapy, Prostate Cancer Targeted Therapy and Others Prostate Cancer. Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Prostate Cancer Treatment Market

The growing prevalence of prostate cancer can be linked to various elements, notably the increasing proportion of elderly individuals worldwide. As more people become aware of the disease and diagnostic techniques advance, the likelihood of identifying prostate cancer at early stages rises. This heightened awareness, combined with robust screening initiatives, has resulted in a notable uptick in reported cases. Consequently, this situation highlights the pressing need for effective treatment strategies and the development of innovative therapeutic options within the market. The confluence of these factors serves to stimulate the progression and expansion of the prostate cancer treatment landscape.

Restraints in the Prostate Cancer Treatment Market

The global prostate cancer treatment market encounters notable challenges, particularly regarding the high costs associated with targeted therapies and immunotherapies. While these advanced treatment options demonstrate considerable potential in enhancing patient outcomes, their affordability poses a significant obstacle. The financial burden of therapies, including immunosuppressants, can be overwhelming for both patients and healthcare systems. This results in limited access to alternative treatments that could significantly improve patient care. Consequently, many individuals face difficulties in managing their healthcare expenses, highlighting the urgent need to address financial barriers to ensure equitable access to these critical, and potentially life-saving, therapies for prostate cancer.

Market Trends of the Prostate Cancer Treatment Market

The prostate cancer treatment market is witnessing a significant shift towards personalized medicine, emphasizing tailored therapies that align with individual genetic and molecular profiles. The application of genomic analysis enables healthcare providers to identify specific biomarkers and genetic mutations within cancer cells, significantly enhancing treatment precision. This approach not only optimizes therapeutic efficacy but also mitigates unnecessary interventions and associated side effects, ultimately improving patient outcomes. Biochemical tests, such as the Prostate Health Index (PHI) and Oncotype DX Genomic Prostate Score, are gaining prominence in identifying candidates for targeted therapies, such as olaparib and rucaparib, which address specific DNA repair pathway alterations. This trend underscores the growing demand for innovative, patient-centric approaches in oncological treatment strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Prostate Cancer Treatment Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Hormonal Prostate Cancer Therapy
  • Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
  • Zytiga
  • Gonax
  • Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
  • Lupron
  • Zoladex
  • Eligard
  • Decapeptyl
  • Vantas
  • Others
  • Anti-Androgen
  • Xtandi
  • Casodex
• Prostate Cancer Chemotherapy
  • Taxotere
  • Jevtana
• Prostate Cancer Immunotherapy
  • Provenge
• Prostate Cancer Targeted Therapy
  • Xofigo
• Others Prostate Cancer

Global Prostate Cancer Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospitals Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Global Prostate Cancer Treatment Market Size & CAGR (2026-2033)

• North America (Drug Type, Distribution Channel)
  • US
  • Canada
• Europe (Drug Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IBSA Pharma (IBSA Group) (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alvogen Iceland ehf (Iceland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jerome Stevens Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lannett Co. Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RLC Labs Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations